Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepak Sampath

Showing results (51-60 of 100) with videos related to

Pageof 10
Sort By:
Journal of Medicinal Chemistry|August 20, 2016
Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) InhibitorsMark Zak, Po-Wai Yuen, Xiongcai Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 29, 2015
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitorsAnneleen Daemen, David Peterson, Nisebita Sahu, et al.
Cancer Discovery|November 19, 2020
Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK PathwaysTrang H Pham, Thijs J Hagenbeek, Ho-June Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2013
Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068Yibing Yan, Violeta Serra, Ludmila Prudkin, et al.
Molecular Cancer Therapeutics|September 15, 2011
The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivoJun Chen, Sha Jin, Vivek Abraham, et al.
Molecular Cancer Therapeutics|March 5, 2016
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma ModelsElizabeth A Punnoose, Joel D Leverson, Franklin Peale, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2013
Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor modelsJie Lin, Deepak Sampath, Michelle A Nannini, et al.
Nature Communications|April 20, 2022
Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitorsKristin M Zimmerman Savill, Brian B Lee, Jason Oeh, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2010
Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitorTimothy P Heffron, Megan Berry, Georgette Castanedo, et al.
Journal of Medicinal Chemistry|December 4, 2012
Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activityMichael F T Koehler, Philippe Bergeron, Elizabeth Blackwood, et al.
Pageof 10

Showing results (51-60 of 100) with videos related to

Sort By:
Pageof 10
Journal of Medicinal Chemistry|August 20, 2016
Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) InhibitorsMark Zak, Po-Wai Yuen, Xiongcai Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 29, 2015
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitorsAnneleen Daemen, David Peterson, Nisebita Sahu, et al.
Cancer Discovery|November 19, 2020
Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK PathwaysTrang H Pham, Thijs J Hagenbeek, Ho-June Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2013
Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068Yibing Yan, Violeta Serra, Ludmila Prudkin, et al.
Molecular Cancer Therapeutics|September 15, 2011
The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivoJun Chen, Sha Jin, Vivek Abraham, et al.
Molecular Cancer Therapeutics|March 5, 2016
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma ModelsElizabeth A Punnoose, Joel D Leverson, Franklin Peale, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2013
Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor modelsJie Lin, Deepak Sampath, Michelle A Nannini, et al.
Nature Communications|April 20, 2022
Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitorsKristin M Zimmerman Savill, Brian B Lee, Jason Oeh, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2010
Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitorTimothy P Heffron, Megan Berry, Georgette Castanedo, et al.
Journal of Medicinal Chemistry|December 4, 2012
Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activityMichael F T Koehler, Philippe Bergeron, Elizabeth Blackwood, et al.
Pageof 10